List of Excipients in API TAZAROTENE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing TAZAROTENE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | ASCORBIC ACID | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | BENZYL ALCOHOL | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | BUTYLATED HYDROXYANISOLE | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | BUTYLATED HYDROXYTOLUENE | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | CARBOMER HOMOPOLYMER TYPE B | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | EDETATE DISODIUM | |
| Allergan Inc | TAZORAC | tazarotene | 0023-8335 | HEXYLENE GLYCOL | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing TAZAROTENE
Detailed excipient profiles for TAZAROTENE
Excipient focus: ANHYDROUS CITRIC ACID
TAZAROTENE drug variants containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing ANHYDROUS CITRIC ACID
Excipient focus: ASCORBIC ACID
TAZAROTENE drug variants containing ASCORBIC ACID
TAZAROTENE drug variants not containing ASCORBIC ACID
Excipient focus: BENZYL ALCOHOL
TAZAROTENE drug variants containing BENZYL ALCOHOL
TAZAROTENE drug variants not containing BENZYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Mayne Pharma | tazarotene | 51862-295 |
| Physicians Total Care Inc | tazarotene | 54868-4456 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYANISOLE
TAZAROTENE drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| Almirall LLC | tazarotene | 16110-833 |
| Padagis Israel Pharmaceuticals Ltd | tazarotene | 45802-436 |
| Bryant Ranch Prepack | tazarotene | 72162-2202 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing BUTYLATED HYDROXYANISOLE
Excipient focus: BUTYLATED HYDROXYTOLUENE
TAZAROTENE drug variants containing BUTYLATED HYDROXYTOLUENE
TAZAROTENE drug variants not containing BUTYLATED HYDROXYTOLUENE
Excipient focus: CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES
TAZAROTENE drug variants containing CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Pacific Pharma Inc | tazarotene | 60758-556 |
| Pacific Pharma Inc | tazarotene | 60758-561 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES
Excipient focus: CARBOMER 1342
TAZAROTENE drug variants containing CARBOMER 1342
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-9155 |
| Almirall LLC | tazarotene | 16110-915 |
| Pacific Pharma Inc | tazarotene | 60758-556 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing CARBOMER 1342
Excipient focus: CARBOMER COPOLYMER TYPE A
TAZAROTENE drug variants containing CARBOMER COPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0670 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0764 |
| Mayne Pharma | tazarotene | 68308-745 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing CARBOMER COPOLYMER TYPE A
Excipient focus: CARBOMER COPOLYMER TYPE B
TAZAROTENE drug variants containing CARBOMER COPOLYMER TYPE B
TAZAROTENE drug variants not containing CARBOMER COPOLYMER TYPE B
Excipient focus: CARBOMER HOMOPOLYMER TYPE A
TAZAROTENE drug variants containing CARBOMER HOMOPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing CARBOMER HOMOPOLYMER TYPE A
Excipient focus: CARBOMER HOMOPOLYMER TYPE B
TAZAROTENE drug variants containing CARBOMER HOMOPOLYMER TYPE B
TAZAROTENE drug variants not containing CARBOMER HOMOPOLYMER TYPE B
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
Excipient focus: CETEARETH-12
TAZAROTENE drug variants containing CETEARETH-12
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing CETEARETH-12
Excipient focus: DIETHYL SEBACATE
TAZAROTENE drug variants containing DIETHYL SEBACATE
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing DIETHYL SEBACATE
Excipient focus: DIISOPROPYL ADIPATE
TAZAROTENE drug variants containing DIISOPROPYL ADIPATE
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing DIISOPROPYL ADIPATE
Excipient focus: EDETATE DISODIUM
TAZAROTENE drug variants containing EDETATE DISODIUM
TAZAROTENE drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL CAPRYLOCAPRATE
TAZAROTENE drug variants containing GLYCERYL CAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| Almirall LLC | tazarotene | 16110-915 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing GLYCERYL CAPRYLOCAPRATE
Excipient focus: HEXYLENE GLYCOL
TAZAROTENE drug variants containing HEXYLENE GLYCOL
TAZAROTENE drug variants not containing HEXYLENE GLYCOL
Excipient focus: LIGHT MINERAL OIL
TAZAROTENE drug variants containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing LIGHT MINERAL OIL
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
TAZAROTENE drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
TAZAROTENE drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | tazarotene | 0023-8335 |
| Allergan Inc | tazarotene | 0023-9155 |
| Bausch Health US LLC | tazarotene | 0187-2098 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0804 |
| Cosette Pharmaceuticals Inc | tazarotene | 0713-0805 |
| Almirall LLC | tazarotene | 16110-833 |
| Almirall LLC | tazarotene | 16110-915 |
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
TAZAROTENE drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing METHYLPARABEN
Excipient focus: MINERAL OIL
TAZAROTENE drug variants containing MINERAL OIL
TAZAROTENE drug variants not containing MINERAL OIL
Excipient focus: POLOXAMER 407
TAZAROTENE drug variants containing POLOXAMER 407
TAZAROTENE drug variants not containing POLOXAMER 407
Excipient focus: POLYETHYLENE GLYCOL 400
TAZAROTENE drug variants containing POLYETHYLENE GLYCOL 400
TAZAROTENE drug variants not containing POLYETHYLENE GLYCOL 400
Excipient focus: POLYSORBATE 40
TAZAROTENE drug variants containing POLYSORBATE 40
TAZAROTENE drug variants not containing POLYSORBATE 40
Excipient focus: POTASSIUM CITRATE
TAZAROTENE drug variants containing POTASSIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing POTASSIUM CITRATE
Excipient focus: POTASSIUM SORBATE
TAZAROTENE drug variants containing POTASSIUM SORBATE
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing POTASSIUM SORBATE
Excipient focus: PROPYLPARABEN
TAZAROTENE drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing PROPYLPARABEN
Excipient focus: SODIUM HYDROXIDE
TAZAROTENE drug variants containing SODIUM HYDROXIDE
TAZAROTENE drug variants not containing SODIUM HYDROXIDE
Excipient focus: SODIUM THIOSULFATE
TAZAROTENE drug variants containing SODIUM THIOSULFATE
TAZAROTENE drug variants not containing SODIUM THIOSULFATE
Excipient focus: SORBIC ACID
TAZAROTENE drug variants containing SORBIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Mayne Pharma | tazarotene | 51862-295 |
| Mayne Pharma Inc | tazarotene | 68308-685 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing SORBIC ACID
Excipient focus: SORBITAN MONOOLEATE
TAZAROTENE drug variants containing SORBITAN MONOOLEATE
TAZAROTENE drug variants not containing SORBITAN MONOOLEATE
Excipient focus: SORBITOL
TAZAROTENE drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | tazarotene | 0187-2098 |
| >Company | >Ingredient | >NDC |
TAZAROTENE drug variants not containing SORBITOL
Excipient focus: TROMETHAMINE
TAZAROTENE drug variants containing TROMETHAMINE
TAZAROTENE drug variants not containing TROMETHAMINE
Excipient focus: WATER
TAZAROTENE drug variants containing WATER
TAZAROTENE drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
